Proud of Alex and his team!!

An amazing use of telemedicine - to save a man gored by a bison on his ranch. Great story. cbsnews.com/news/rural-amb…

The preliminary #JPM24 schedule is out.

So proud of Mary - she is so driven to succeed, not just for herself but for those people and causes she cares about, including environmental causes. Thanks Lower Gwynedd Twp. for recognizing her!

👁 Heading to #ASCRS in Boston? Let’s connect! 👁️ I’m looking forward to reuniting with my fellow #eyecare enthusiasts and delving into the latest and greatest developments in #ophthalmology. Reach out! #ASCRS2024

Nice piece about late-breaking data from Freeline at #ASGCT2024 from its gene therapy study in #Gaucher disease endpts.com/freeline-unvei…

Great interview with AviadoBio CEO Lisa Deschamps explaining the company's investigational #genetherapy and unique delivery for #FTD, a devastating form of dementia. The new office and lab in Canary Wharf looks beautiful!

Happy 10th anniversary Stoke! Amazing team of people doing great work to help patients and families with Dravet syndrome - lots to celebrate (and lots of work ahead!).

Exciting announcement: Freeline is now Spur Therapeutics! We’re building on our successes to keep advancing the practice of genetic medicine, with the goal of bringing life-changing therapies to more people around the world. Learn more: spurtherapeutics.com

Our CEO Michael Parini sat down with BiotechTV for an insightful discussion about our recent rebrand, our approach to developing transformational gene therapies, and our mission to redefine what gene therapy can do for patients.

Our CMO Dr. David Cooper spoke with NeurologyLive® to discuss the details of ASPIRE-FTD, a Ph. 1/2 clinical trial evaluating our investigational #GeneTherapy for #FrontotemporalDementia with GRN mutations (FTD-GRN). Learn more below. #BioTech #Dementia

Loved this PR Daily article about strategic media relations - this is what I try to practice and teach our #PR team. Critical to know what these influential reporters want & how they work to assess if a client can fit in. prdaily.com/flip-the-scrip…

Company News: Adaptimmune's CEO discusses last night's FDA accelerated approval of TECELRA, a TCR-based engineered cell therapy for synovial sarcoma. Full video: biotechtv.com/post/adaptimmu…

Behind the Science: Stoke Therapeutics's CEO Ed Kaye on using RNA medicines to upregulate protein expression, and the company's progress in Dravet Syndrome. $STOK Full video: biotechtv.com/post/stoke-the…

The Backstory: During a visit to Stoke Therapeutics yesterday, we met co-founder Isabel Aznarez 🏳️‍🌈🇺🇦 and heard the story of how the company was founded and why the focus on gene expression upregulation. See more at BiotechTV.com

I loved every word of this article. I was expecting 2SP to be on the list though!

We’re expanding our pipeline with a new clinical-stage asset, strengthening our leadership in MASH. Read more here: bit.ly/4qe3DlK

Today we announced a global license agreement for six pre-clinical siRNA programs. Read more about it and our expanded pipeline here: bit.ly/4bObS3H

Sharon Mates, founder of Intra-Cellular on her "elevator advice" to young scientists: "dumb it down." If that isn't an endorsement for a good Communications team I don't know what is! #STATBreakthrough

A bold statement...but wow, imagine if that's where this leads. Looking forward to seeing all the data. endpoints.news/its-just-the-b…